{"result": {"id": "612443c0-b2b9-4274-af60-ca0c20ea5782", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>J HYPERTENS<|>ORGANIZATION<|>A medical journal publishing research on hypertension and cardiovascular outcomes>  \n##  \n(\"entity\"<|>N ENGL J MED<|>ORGANIZATION<|>A prestigious medical journal publishing studies on hypertension treatments and cardiovascular events>  \n##  \n(\"entity\"<|>CAN J CARDIOL<|>ORGANIZATION<|>A medical journal focusing on cardiology and hypertension research>  \n##  \n(\"entity\"<|>INT J CLIN PRACT<|>ORGANIZATION<|>A medical journal publishing clinical studies on hypertension management>  \n##  \n(\"entity\"<|>CIRC RES<|>ORGANIZATION<|>A journal publishing research on cardiovascular and hypertension-related studies>  \n##  \n(\"entity\"<|>THORAX<|>ORGANIZATION<|>A medical journal publishing studies on lung diseases and associated hypertension conditions>  \n##  \n(\"entity\"<|>PHARMACOL REV<|>ORGANIZATION<|>A journal publishing reviews on pharmacological treatments for hypertension>  \n##  \n(\"entity\"<|>HYPERTENS RES<|>ORGANIZATION<|>A journal specializing in hypertension research and treatment studies>  \n##  \n(\"entity\"<|>J AM COLL CARDIOL<|>ORGANIZATION<|>A leading journal publishing research on cardiovascular diseases and hypertension>  \n##  \n(\"entity\"<|>J CLIN HYPERTENS<|>ORGANIZATION<|>A journal focused on clinical hypertension research and treatments>  \n##  \n(\"entity\"<|>CARDIOLOGY<|>ORGANIZATION<|>A journal publishing research on cardiovascular diseases, including hypertension>  \n##  \n(\"entity\"<|>CHINESE HOSPITAL PHARMACY JOURNAL<|>ORGANIZATION<|>A journal publishing expert consensus on hypertension treatments in China>  \n##  \n(\"entity\"<|>J CLIN PHARMACOL<|>ORGANIZATION<|>A journal publishing pharmacokinetic and pharmacodynamic studies on hypertension drugs>  \n##  \n(\"relationship\"<|>J HYPERTENS<|>JAMA NETW OPEN<|>Both journals publish research on hypertension treatments<|>4>  \n##  \n(\"relationship\"<|>N ENGL J MED<|>JAMA NETW OPEN<|>Both are leading medical journals publishing hypertension research<|>4>  \n##  \n(\"relationship\"<|>CAN J CARDIOL<|>JAMA NETW OPEN<|>Both publish studies on hypertension and cardiovascular outcomes<|>4>  \n##  \n(\"relationship\"<|>INT J CLIN PRACT<|>JAMA NETW OPEN<|>Both journals publish clinical studies on hypertension management<|>4>  \n##  \n(\"relationship\"<|>CIRC RES<|>JAMA NETW OPEN<|>Both publish research on hypertension and cardiovascular health<|>4>  \n##  \n(\"relationship\"<|>THORAX<|>JAMA NETW OPEN<|>Both publish studies on hypertension-related conditions<|>3>  \n##  \n(\"relationship\"<|>PHARMACOL REV<|>JAMA NETW OPEN<|>Both publish reviews on hypertension treatments<|>4>  \n##  \n(\"relationship\"<|>HYPERTENS RES<|>JAMA NETW OPEN<|>Both specialize in hypertension research<|>5>  \n##  \n(\"relationship\"<|>J AM COLL CARDIOL<|>JAMA NETW OPEN<|>Both publish leading research on hypertension and cardiovascular diseases<|>5>  \n##  \n(\"relationship\"<|>J CLIN HYPERTENS<|>JAMA NETW OPEN<|>Both focus on clinical hypertension research<|>5>  \n##  \n(\"relationship\"<|>CARDIOLOGY<|>JAMA NETW OPEN<|>Both publish studies on hypertension and cardiovascular outcomes<|>4>  \n##  \n(\"relationship\"<|>CHINESE HOSPITAL PHARMACY JOURNAL<|>JAMA NETW OPEN<|>Both publish expert consensus on hypertension treatments<|>3>  \n##  \n(\"relationship\"<|>J CLIN PHARMACOL<|>JAMA NETW OPEN<|>Both publish pharmacokinetic studies on hypertension drugs<|>4>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559018, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 942, "prompt_tokens": 6319, "total_tokens": 7261, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2944}, "prompt_cache_hit_tokens": 2944, "prompt_cache_miss_tokens": 3375}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ystematicreview andnetworkmeta-analysis [J]. JAMANetw Open,2020,3(2) :e1921618.\n[261]  ChalmersJ, MouradJJ, Brzozowska-VillatteR, etal. Benefitof treatmentbasedonindapamidemostlycombinedwithperindopril on mortality and cardiovascular outcomes: a pooled analysis of fourtrials[J]. J Hypertens,2023,41(3) :508-515.\n[262]  ThomopoulosC, ParatiG, ZanchettiA.  Effects ofblood pres- sure-loweringonoutcomeincidenceinhypertension: 5.  Head-to-\n\n\nhead comparisons of various classes of antihypertensive drugs- overview and meta-analyses[J]. J Hypertens,2015,33(7) : 1321- 1341.\n[263]  IshaniA, CushmanWC, LeathermanSM, etal. Chlorthalidone vs.   hydrochlorothiazide for hypertension-cardiovascular events [J]. N EnglJ Med,2022,387(26) :2401-2410.\n[264]  KuyperLM, Khan NA.  Atenololvs nonatenololβ-blockers for thetreatmentofhypertension: a meta-analysis[J] Can J Cardi- ol,2014,30(5Suppl) :S47-S53.\n[265]  DearyAJ, Schumann AL, MurfetH, etal. Double-blind, pla- cebo-controlledcrossovercomparisonoffiveclassesofantihyper- tensivedrugs[J]. J Hypertens,2002,20(4) :771-777.\n[266]  LiuJ, LuX, Chen L, etal.  Expertconsensus on the manage- mentofhypertensionintheyoungandmiddle-agedChinesepop- ulation[J]. IntJ ClinPract,2019:e13426.\n[267]  GrassiG, Mark A, EslerM.  The sympathetic nervous system alterationsin human hypertension[J]. Circ Res, 2015, 116(6) : 976-990.\n[268]  Stefan MS, RothbergMB, PriyaA, etal. Association between β-blocker therapy and outcomes in patients hospitalised with acuteexacerbationsofchronic obstructive lung disease with un- derlying ischaemic heart disease, heart failure or hypertension [J] Thorax,2012,67(11) :977-984.\n[269]  LevinER, GardnerDG, SamsonetWK, etal. Natriureticpep- tides[J]. N EnglJ Med,1998,339(5) :321-328.\n[270]  ArendseLB, DanserA, PoglitschM, et al.  Novel therapeutic approachestargetingtherenin-angiotensin system andassociated peptidesin hypertension and heart failure[J]. Pharmacol Rev,  2019,71(4) :539-570.\n[271]  ZhangJ, ZhangW , YanJ, etal. Efficacy and safety ofsacubi- tril/allisartanforthetreatmentofprimaryhypertension: aphase 2 randomized, double-blind study[J]. Hypertens Res, 2023, 46\n(8) :2024-2032.\n[272]  ZhangW , ZhangJ, YanJ, etal. Efficacy and safety ofsacubi- tril/allisartanforthetreatmentofprimaryhypertension: aphase 3 randomized, double-blind study[J]. JAm CollCardiol, 2024,  83(13Suppl) :1705.\n[273]  中国药学会医院药学专业委员会 , 中华医学会老年医学分会.  沙 库巴曲缬沙坦钠共晶物药学特性专家共识[J]. 中国医院药学杂 志 ,2021,41(19) :1931-1934.\n[274]  GuJ, NoeA, ChandraP, etal. Pharmacokineticsand pharma- codynamicsofLCZ696, anoveldual-actingangiotensinreceptor- neprilysin inhibitor(ARNi) [J]. J Clin Pharmacol,2010, 50(4) :  401-414.\n[275]  LinDS, WangTD, BuranakitjaroenP, etal. Angiotensinrecep- torneprilysin inhibitor as a novel antihypertensive drug:  evi- dence from Asia and around the globe[J]. J Clin Hypertens (Greenwich) ,2021,23(3) :556-567.\n[276]  GengQ, YanR, WangZ, etal. EffectsofLCZ696(sacubitril/ valsartan)  on blood pressure in patients with hypertension:  a meta-analysis of randomized controlled trials[J].  Cardiology,  2020,145(9) :589-598.\n[277]  WangJG, YukisadaK, SibuloAJr, etal. Efficacyandsafetyof sacubitril/valsartan(LCZ696) add-ontoamlodipineinAsianpa- tients with systolic hypertension uncontrolled with aml\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>JAMA NETW OPEN<|>ORGANIZATION<|>A medical journal publishing systematic reviews and network meta-analyses on various topics including hypertension treatments>  \n##  \n(\"entity\"<|>CHALMERS J<|>PERSON<|>A researcher involved in studies on hypertension treatments, particularly indapamide and perindopril>  \n##  \n(\"entity\"<|>MOURAD JJ<|>PERSON<|>A researcher contributing to studies on hypertension treatments>  \n##  \n(\"entity\"<|>BRZOZOWSKA-VILLATTE R<|>PERSON<|>A researcher involved in hypertension treatment studies>  \n##  \n(\"entity\"<|>THOMOPOULOS C<|>PERSON<|>A researcher studying blood pressure-lowering treatments and their effects>  \n##  \n(\"entity\"<|>PARATI G<|>PERSON<|>A researcher specializing in hypertension and cardiovascular outcomes>  \n##  \n(\"entity\"<|>ZANCHETTI A<|>PERSON<|>A researcher involved in meta-analyses of antihypertensive drugs>  \n##  \n(\"entity\"<|>ISHANI A<|>PERSON<|>A researcher comparing chlorthalidone and hydrochlorothiazide for hypertension treatment>  \n##  \n(\"entity\"<|>CUSHMAN WC<|>PERSON<|>A researcher involved in hypertension and cardiovascular event studies>  \n##  \n(\"entity\"<|>LEATHERMAN SM<|>PERSON<|>A researcher contributing to hypertension treatment research>  \n##  \n(\"entity\"<|>KUYPER LM<|>PERSON<|>A researcher comparing atenolol and non-atenolol β-blockers for hypertension>  \n##  \n(\"entity\"<|>KHAN NA<|>PERSON<|>A researcher involved in meta-analyses of hypertension treatments>  \n##  \n(\"entity\"<|>DEARY AJ<|>PERSON<|>A researcher conducting double-blind studies on antihypertensive drugs>  \n##  \n(\"entity\"<|>SCHUMANN AL<|>PERSON<|>A researcher involved in hypertension drug comparison studies>  \n##  \n(\"entity\"<|>MURFET H<|>PERSON<|>A researcher contributing to antihypertensive drug trials>  \n##  \n(\"entity\"<|>LIU J<|>PERSON<|>A researcher involved in expert consensus on hypertension management>  \n##  \n(\"entity\"<|>LU X<|>PERSON<|>A researcher contributing to hypertension management studies>  \n##  \n(\"entity\"<|>CHEN L<|>PERSON<|>A researcher involved in hypertension treatment consensus>  \n##  \n(\"entity\"<|>GRASSI G<|>PERSON<|>A researcher studying the sympathetic nervous system in hypertension>  \n##  \n(\"entity\"<|>MARK A<|>PERSON<|>A researcher investigating hypertension and the sympathetic nervous system>  \n##  \n(\"entity\"<|>ESLER M<|>PERSON<|>A researcher studying hypertension and cardiovascular alterations>  \n##  \n(\"entity\"<|>STEFAN MS<|>PERSON<|>A researcher studying β-blocker therapy outcomes in hypertension>  \n##  \n(\"entity\"<|>ROTHBERG MB<|>PERSON<|>A researcher involved in studies on hypertension and cardiovascular outcomes>  \n##  \n(\"entity\"<|>PRIYA A<|>PERSON<|>A researcher contributing to hypertension and lung disease studies>  \n##  \n(\"entity\"<|>LEVIN ER<|>PERSON<|>A researcher studying natriuretic peptides in hypertension>  \n##  \n(\"entity\"<|>GARDNER DG<|>PERSON<|>A researcher involved in natriuretic peptide studies>  \n##  \n(\"entity\"<|>SAMSONET WK<|>PERSON<|>A researcher contributing to natriuretic peptide research>  \n##  \n(\"entity\"<|>ARENDSE LB<|>PERSON<|>A researcher investigating novel hypertension therapies>  \n##  \n(\"entity\"<|>DANSER A<|>PERSON<|>A researcher studying the renin-angiotensin system in hypertension>  \n##  \n(\"entity\"<|>POGLITSCH M<|>PERSON<|>A researcher involved in hypertension and heart failure studies>  \n##  \n(\"entity\"<|>ZHANG J<|>PERSON<|>A researcher studying sacubitril/allisartan for hypertension treatment>  \n##  \n(\"entity\"<|>ZHANG W<|>PERSON<|>A researcher involved in hypertension drug trials>  \n##  \n(\"entity\"<|>YAN J<|>PERSON<|>A researcher contributing to hypertension treatment studies>  \n##  \n(\"entity\"<|>GU J<|>PERSON<|>A researcher studying pharmacokinetics of LCZ696 for hypertension>  \n##  \n(\"entity\"<|>NOE A<|>PERSON<|>A researcher involved in hypertension drug development>  \n##  \n(\"entity\"<|>CHANDRA P<|>PERSON<|>A researcher contributing to hypertension treatment research>  \n##  \n(\"entity\"<|>LIN DS<|>PERSON<|>A researcher studying angiotensin receptor neprilysin inhibitors for hypertension>  \n##  \n(\"entity\"<|>WANG TD<|>PERSON<|>A researcher involved in hypertension drug studies>  \n##  \n(\"entity\"<|>BURANAKITJAROEN P<|>PERSON<|>A researcher contributing to hypertension treatment research>  \n##  \n(\"entity\"<|>GENG Q<|>PERSON<|>A researcher studying LCZ696 effects on blood pressure>  \n##  \n(\"entity\"<|>YAN R<|>PERSON<|>A researcher involved in hypertension meta-analyses>  \n##  \n(\"entity\"<|>WANG Z<|>PERSON<|>A researcher contributing to hypertension treatment studies>  \n##  \n(\"entity\"<|>WANG JG<|>PERSON<|>A researcher studying sacubitril/valsartan for hypertension>  \n##  \n(\"entity\"<|>YUKISADA K<|>PERSON<|>A researcher involved in hypertension drug trials>  \n##  \n(\"entity\"<|>SIBULO A JR<|>PERSON<|>A researcher contributing to hypertension treatment research>  \n##  \n(\"entity\"<|>CHINESE PHARMACEUTICAL ASSOCIATION<|>ORGANIZATION<|>An organization involved in expert consensus on hypertension treatments>  \n##  \n(\"entity\"<|>CHINESE GERIATRICS SOCIETY<|>ORGANIZATION<|>An organization contributing to expert consensus on hypertension management>  \n##  \n(\"relationship\"<|>CHALMERS J<|>JAMA NETW OPEN<|>Chalmers J contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>MOURAD JJ<|>JAMA NETW OPEN<|>Mourad JJ contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>BRZOZOWSKA-VILLATTE R<|>JAMA NETW OPEN<|>Brzozowska-Villatte R contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>THOMOPOULOS C<|>JAMA NETW OPEN<|>Thomopoulos C contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>PARATI G<|>JAMA NETW OPEN<|>Parati G contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>ZANCHETTI A<|>JAMA NETW OPEN<|>Zanchetti A contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>ISHANI A<|>JAMA NETW OPEN<|>Ishani A contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>CUSHMAN WC<|>JAMA NETW OPEN<|>Cushman WC contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>LEATHERMAN SM<|>JAMA NETW OPEN<|>Leatherman SM contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>KUYPER LM<|>JAMA NETW OPEN<|>Kuyper LM contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>KHAN NA<|>JAMA NETW OPEN<|>Khan NA contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>DEARY AJ<|>JAMA NETW OPEN<|>Deary AJ contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>SCHUMANN AL<|>JAMA NETW OPEN<|>Schumann AL contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>MURFET H<|>JAMA NETW OPEN<|>Murfet H contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>LIU J<|>JAMA NETW OPEN<|>Liu J contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>LU X<|>JAMA NETW OPEN<|>Lu X contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>CHEN L<|>JAMA NETW OPEN<|>Chen L contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>GRASSI G<|>JAMA NETW OPEN<|>Grassi G contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>MARK A<|>JAMA NETW OPEN<|>Mark A contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>ESLER M<|>JAMA NETW OPEN<|>Esler M contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>STEFAN MS<|>JAMA NETW OPEN<|>Stefan MS contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>ROTHBERG MB<|>JAMA NETW OPEN<|>Rothberg MB contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>PRIYA A<|>JAMA NETW OPEN<|>Priya A contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>LEVIN ER<|>JAMA NETW OPEN<|>Levin ER contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>GARDNER DG<|>JAMA NETW OPEN<|>Gardner DG contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>SAMSONET WK<|>JAMA NETW OPEN<|>Samsonet WK contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>ARENDSE LB<|>JAMA NETW OPEN<|>Arendse LB contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>DANSER A<|>JAMA NETW OPEN<|>Danser A contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>POGLITSCH M<|>JAMA NETW OPEN<|>Poglitsch M contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>ZHANG J<|>JAMA NETW OPEN<|>Zhang J contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>ZHANG W<|>JAMA NETW OPEN<|>Zhang W contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>YAN J<|>JAMA NETW OPEN<|>Yan J contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>GU J<|>JAMA NETW OPEN<|>Gu J contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>NOE A<|>JAMA NETW OPEN<|>Noe A contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>CHANDRA P<|>JAMA NETW OPEN<|>Chandra P contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>LIN DS<|>JAMA NETW OPEN<|>Lin DS contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>WANG TD<|>JAMA NETW OPEN<|>Wang TD contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>BURANAKITJAROEN P<|>JAMA NETW OPEN<|>Buranakitjaroen P contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>GENG Q<|>JAMA NETW OPEN<|>Geng Q contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>YAN R<|>JAMA NETW OPEN<|>Yan R contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>WANG Z<|>JAMA NETW OPEN<|>Wang Z contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>WANG JG<|>JAMA NETW OPEN<|>Wang JG contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>YUKISADA K<|>JAMA NETW OPEN<|>Yukisada K contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>SIBULO A JR<|>JAMA NETW OPEN<|>Sibulo A Jr contributed to research published in JAMA Netw Open<|>5>  \n##  \n(\"relationship\"<|>CHINESE PHARMACEUTICAL ASSOCIATION<|>CHINESE GERIATRICS SOCIETY<|>Both organizations collaborated on expert consensus for hypertension treatments<|>7>  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_71233022bb1e7d165515a8408ff2758f238f36517af4f2e93e0bc6299a764dc7_v2"}